NCT07402473 2026-02-11
EUREKA Study:Phase 2 Study to Optimize Neoadjuvant Therapy in HER2-positive Early-stage Breast Cancer
Rutgers, The State University of New Jersey
Phase 2 Not yet recruiting
Clinical Trials
9 trialsNCT07246317 2025-11-28
Evaluation of Neoadjuvant Therapy With Trastuzumab, Pertuzumab, Docetaxel, and QL1706 in Early or Locally Advanced HER2+ Breast Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting
NCT07220135 2025-10-23
NeoTHERa
University of Kansas Medical Center
Phase 2 Not yet recruiting
NCT07129018 2025-08-19
Trastuzumab Rezetecan Combined With Pertuzumab and Iparomlimab and Tuvonralimab for Biliary Tract Cancer
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2 Not yet recruiting
NCT07116824 2025-08-12
HB1801 Combined Treatment of HER2-positive Breast Cancer
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 2 Not yet recruiting
NCT07047755 2025-07-02
Trastuzumab Rezetecan Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC
Henan Cancer Hospital
Phase 2 Not yet recruiting
NCT06510465 2024-07-19
NeoURANIA
RenJi Hospital
Phase 2 Not yet recruiting
NCT05983094 2023-08-09
Study of Utidelone Based Neoadjuvant Treatment on Early High-risk or Locally Advanced Breast Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Not yet recruiting
NCT04301375 2020-03-10
ELPIS
Hospital Clinic of Barcelona
Phase 2 Not yet recruiting